Kyverna Therapeutics (KYTX) Common Equity (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Common Equity data on file, last reported at $195.6 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 12.69% year-over-year to $195.6 million; the trailing twelve-month figure through Mar 2026 stood at $195.6 million (down 12.69% YoY), and the FY2025 full-year result was $232.3 million, down 12.87% from the prior year.
• Common Equity for Q1 2026 stood at $195.6 million, down from $232.3 million in the prior quarter.
• Across five years, Common Equity topped out at $361.0 million in Q1 2024 and bottomed at -$111.8 million in Q3 2023.
• The 4-year median for Common Equity is $195.6 million (2026), against an average of $149.6 million.
• The widest annual swing landed in 2024, when Common Equity soared 2128.97%; it then slumped 49.8% in 2025.
• A 4-year view of Common Equity shows it stood at -$13.1 million in 2023, then jumped by 2128.97% to $266.6 million in 2024, then retreated by 12.87% to $232.3 million in 2025, then slipped by 15.8% to $195.6 million in 2026.
• The last three Common Equity figures came in at $195.6 million (Q1 2026), $232.3 million (Q4 2025), and $151.9 million (Q3 2025), per Business Quant data.

Peer Comparison